TheraP: A Randomised Phase 2 Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer (ANZUP Protocol 1603)
Phase of Trial: Phase II
Latest Information Update: 30 Oct 2018
At a glance
- Drugs PSMA 617 (Primary) ; Cabazitaxel
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms TheraP
- 31 Aug 2018 Biomarkers information updated
- 26 Jun 2018 According to an Endocyte media release, an image of PET scans of eight patients before treatment with 177Lu-PSMA-617 and at three months following treatment from this trial was selected at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting as the Image of the Year.
- 16 May 2018 According to Endocyte media release, data from this trial will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.